Expression of IgG Antibodies in Mammalian Cells

  • Thomas JostockEmail author
  • Jiandong Li
Part of the Springer Protocols Handbooks book series (SPH)

Production of IgG antibodies is usually done in mamalian cells. Predominantly, chinese hamster ovary (CHO) cells are used for generating stably transfected cell lines and for manufacturing. In addition to large scale manufacturing, stably transfected CHO cells are also well suited for repeated laboratory scale prodution of antibodies. Once generated, such cell lines can be expanded for production according to the antibody amounts needed. In this chapter, a general introduction to CHO cell line deveopment for antibody expression and a more detailed example protocol for establishing a basic CHO cell antibody expression system are given. All high performance stable mammalian expression systems are result of intensive optimisation efforts and strongly depend on the vector, selection system, host cell line and media that are used. The basic protocol described here is based on generally available materials and should be only seen as a starting point for laboratory scale production of antibodies in CHO cells.


Chinese Hamster Ovarian Cell Selection System Selectable Marker Gene Host Cell Line Antibody Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58(5–6):671–85PubMedCrossRefGoogle Scholar
  2. Borman AM, Deliat FG, Kean KM (1994) Sequences within the poliovirus internal ribosome entry segment control viral RNA synthesis. Embo J 13(13):3149–57PubMedGoogle Scholar
  3. Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, MacLean A, Sisk W, Thill G (2003) A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J Immunol Methods 277(1–2):141–55PubMedCrossRefGoogle Scholar
  4. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23(5):584–90PubMedCrossRefGoogle Scholar
  5. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten DJ, Logtenberg T, Bout A (2003) High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 19(1):163–8PubMedCrossRefGoogle Scholar
  6. Jostock T (2009) Reducing cycle time for cell line development. Cell line development and engineering conference. Informa, BerlinGoogle Scholar
  7. Jostock T, Vanhove M, Brepoels E, Van Gool R, Daukandt M, Wehnert A, Van Hegelsom R, Dransfield D, Sexton D, Devlin M, Ley A, Hoogenboom H, Mullberg J (2004) Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 289(1–2):65–80PubMedCrossRefGoogle Scholar
  8. Jostock T, Sewalt R, Drewello D, Lang S, Dennler S, Ortlepp M, Wichter J, Nommay A, Dragic Z, van der Vaart H, Wilms B, Knopf HP (2008) Evaluation of the STAR Technology. European Biotechnology News 7:33–36Google Scholar
  9. Kaloff CR, Haas IG (1995) Coordination of immunoglobulin chain folding and immunoglobulin chain assembly is essential for the formation of functional IgG. Immunity 2(6):629–37PubMedCrossRefGoogle Scholar
  10. Kalwy S, Rance J, Young R (2006) Toward more efficient protein expression: keep the message simple. Mol Biotechnol 34(2):151–6PubMedCrossRefGoogle Scholar
  11. Kaufman RJ, Davies MV, Wasley LC, Michnick D (1991) Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res 19(16):4485–90PubMedCrossRefGoogle Scholar
  12. Lee G (2008) Cell line development using a Per.C6 host cell line. Cell Line Development and Engineering Conference. Informa, San Diego, CAGoogle Scholar
  13. Li J, Menzel C, Meier D, Zhang C, Dübel S, Jostock T (2007a) A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. J Immunol Methods 318(1–2):113–24PubMedCrossRefGoogle Scholar
  14. Li J, Zhang C, Jostock T, Dübel S (2007b) Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Eng Des Sel 20(10):491–6PubMedCrossRefGoogle Scholar
  15. Montano RF, Morrison SL (2002) Influence of the isotype of the light chain on the properties of IgG. J Immunol 168(1):224–31PubMedGoogle Scholar
  16. Puck TT (1958) Genetics of somatic mammalian cells. J Exp Med 108:945–955PubMedCrossRefGoogle Scholar
  17. Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC (2005) On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog 21(1):122–33PubMedCrossRefGoogle Scholar
  18. Urlaub G, Chasin LA (1980) Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci USA 77(7):4216–20PubMedCrossRefGoogle Scholar
  19. Urlaub G, Kas E, Carothers AM, Chasin LA (1983) Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell 33(2):405–12PubMedCrossRefGoogle Scholar
  20. Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393–8PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Novartis BiologicsProtein Sciences and ProductionBaselSwitzerland
  2. 2.National Institute for Viral Diseases Control and PreventionBeijingChina

Personalised recommendations